SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
1st Translational Research Conference
Chronic Lymphocytic Leukaemia 2020
E-CONFERENCE
GENERAL INFORMATION
On demand Conference : November 5, 2020 – November 29, 2020
Live Conference : November 16-19, 2020
https://chronic-lymphocytic-leukaemia-2020.esh.live/
Copyrights
Conference participants are requested to treat the information presented during ESH meetings as privileged communication.
Presentation of data during ESH conferences does not constitute publication in the sense of patent law and the data
presented therefore retains unpublished status.
Ask the faculty
The E-Conference platform allows you to submit your question online.
Simply use the “ask a question” field when viewing the presentations/discussions.
Twitter
Contribute to the Twitter discussion online using #ESHCLL2020
CME Accreditation
The programme of the ESH 1st Translational Research Confrence on Chronic Lymphocytic Leukaemia has been reviewed and
approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH). The EHA-CME Unit has
approved this educational activity for a maximum number of 13 CME credits. Each physician should only claim credits for
time that she/he actually spent in the educational activity.
The ESH 1st Translational Research Confrence on Chronic Lymphocytic Leukaemia is committed to providing unbiased,
balanced and objective educational and scientific programmes. In accordance with EBAH guidelines, all planners and speakers
are asked to provide disclosures of their relevant financial relationships, which are available for audience review via a slide
presentation. The CME provider has a mechanism in place to identify and resolve any conflicts of interest prior to the start of
each presentation. Audience members will be asked to assess each presentation for the presence/absence of commercial
bias.